<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867097</url>
  </required_header>
  <id_info>
    <org_study_id>ES-201</org_study_id>
    <nct_id>NCT03867097</nct_id>
  </id_info>
  <brief_title>Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eicos Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eicos Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to&#xD;
      evaluate the effect of iloprost on the symptomatic relief of Raynaud's Phenomenon attacks in&#xD;
      subjects with symptomatic Raynaud's Phenomenon secondary to Systemic Sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2019</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of symptomatic RP attacks</measure>
    <time_frame>Day 8 - Day 21 will be compared to baseline</time_frame>
    <description>The primary efficacy parameter is the change in the weekly frequency of symptomatic RP attacks from baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Raynaud Phenomenon Secondary to Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iloprost Injection, for intravenous use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV infusion</intervention_name>
    <description>Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloprost Injection, for intravenous use</intervention_name>
    <description>Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.</description>
    <arm_group_label>Iloprost Injection, for intravenous use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects must be greater than or equal to 18 years of age&#xD;
&#xD;
          -  Subjects must have a diagnosis of Systemic Sclerosis&#xD;
&#xD;
          -  Subjects must have a diagnosis or history of Raynaud's Phenomenon&#xD;
&#xD;
          -  Subjects must have a minimum of 10 symptomatic Raynaud's Phenomenon attacks&#xD;
&#xD;
          -  Female subjects of childbearing potential and male subjects must agree to use&#xD;
             contraception for the duration of the study&#xD;
&#xD;
          -  Subjects must be willing and able to comply with the study requirements and give&#xD;
             informed consent for participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects who are pregnant or breastfeeding&#xD;
&#xD;
          -  Subjects with systolic blood pressure &lt;85 mmHg&#xD;
&#xD;
          -  Subjects with an estimated glomerular filtration rate &lt;30 mL/min/1.73 m2&#xD;
&#xD;
          -  Subjects with Child-Pugh Class B or Class C liver disease or an alanine&#xD;
             aminotransferase and/or aspartate aminotransferase value &gt;3 Ã— the upper limit of&#xD;
             normal at screening.&#xD;
&#xD;
          -  Subjects with gangrene, digital ulcer infection, or requirement of cervical or digital&#xD;
             sympathectomy&#xD;
&#xD;
          -  Subjects with intractable diarrhea or vomiting&#xD;
&#xD;
          -  Subjects with a risk of clinically significant bleeding events including those with&#xD;
             coagulation or platelet disorders&#xD;
&#xD;
          -  Subjects with a history of major trauma or hemorrhage&#xD;
&#xD;
          -  Subjects with clinically significant chronic intermittent bleeding such as active&#xD;
             gastric antral vascular ectasia or active peptic ulcer disease&#xD;
&#xD;
          -  Subjects who have had any cerebrovascular events&#xD;
&#xD;
          -  Subjects with a history of myocardial infarction or unstable angina within 6 months of&#xD;
             screening&#xD;
&#xD;
          -  Subjects with acute or chronic congestive heart failure&#xD;
&#xD;
          -  Subjects with a history of life-threatening cardiac arrhythmias&#xD;
&#xD;
          -  Subjects with a history of hemodynamically significant aortic or mitral valve disease&#xD;
&#xD;
          -  Subjects with more than mild restrictive or congestive cardiomyopathy uncontrolled by&#xD;
             medication or implanted device.&#xD;
&#xD;
          -  Subjects with known pulmonary hypertension, pulmonary arterial hypertension, or&#xD;
             pulmonary veno-occlusive disease&#xD;
&#xD;
          -  Subjects with a history of significant restrictive lung disease defined as forced&#xD;
             vital capacity &lt;45% predicted and diffusing capacity of the lungs for carbon monoxide&#xD;
             &lt;40% predicted (uncorrected for hemoglobin).&#xD;
&#xD;
          -  Subjects with a history of cervical or digital sympathectomy&#xD;
&#xD;
          -  Subjects with scleroderma renal crisis&#xD;
&#xD;
          -  Subjects with a concomitant life-threatening disease with a life expectancy &lt;12 months&#xD;
&#xD;
          -  Subjects who have a clinically significant disorder, that in the opinion of the&#xD;
             Investigator, could contraindicate the administration of study drug, affect&#xD;
             compliance, interfere with study evaluations, or confound the interpretation of study&#xD;
             results&#xD;
&#xD;
          -  Subjects who have taken or are currently taking any parenteral, inhaled, or oral&#xD;
             prostacyclin or prostacyclin receptor agonists&#xD;
&#xD;
          -  Subjects must not initiate dosing of oral, topical, or intravenous (IV) vasodilators&#xD;
             or if currently receiving any vasodilator must have been stably medicated&#xD;
&#xD;
          -  Subjects with any history of acetaminophen intolerability&#xD;
&#xD;
          -  Subjects with any malignancy that requires treatment during the study period, that has&#xD;
             required treatment within 1 year of screening, or that is currently not in remission.&#xD;
&#xD;
          -  Subjects who have used any investigational medication or device for any indication&#xD;
             within 30 days or 5 half-lives (whichever is longer)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wade Benton, Pharm D</last_name>
    <role>Study Director</role>
    <affiliation>Civibio Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research, PLLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Arthritis Care Center of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center - Department of Rheumatology</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Toledo Medical Center (UTMC) - Ruppert Health Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest Rheumatology PLLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>systemic sclerosis</keyword>
  <keyword>raynaud phenomenon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Raynaud Disease</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

